Ottawa, Canada

Yanal Murad

This inventor holds 1 USPTO granted patent, plus 3 CIPO patents and 1 EPO patent. Top assignee: National Research Council of Canada. Active years: 2015.


% Patents Active = 100.0


 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yanal Murad - Innovator in Antibody Therapeutics

Introduction

Yanal Murad is a notable inventor based in Ottawa, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic tools. His work focuses on isolated or purified antibodies that target CEACAM6, a protein involved in various diseases.

Latest Patents

Yanal Murad holds a patent for "Anti-CEACAM6 antibodies and uses thereof." This invention relates to antibodies or fragments that are specific for CEACAM6 and their applications as therapeutic or diagnostic tools. The patent describes both in vivo and in vitro methods for diagnosis and therapeutic approaches, highlighting the potential of these antibodies in medical applications.

Career Highlights

Yanal Murad is affiliated with the National Research Council of Canada, where he conducts research and development in the field of antibody therapeutics. His innovative work has positioned him as a key figure in advancing medical science through the use of targeted therapies.

Collaborations

Yanal has collaborated with several esteemed colleagues, including Jianbing Zhang and Toya Nath Baral, who contribute to his research efforts. Their combined expertise enhances the potential impact of their work in the field of biotechnology.

Conclusion

Yanal Murad's contributions to the development of anti-CEACAM6 antibodies exemplify the importance of innovation in medical research. His work not only advances scientific knowledge but also holds promise for future therapeutic applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…